Department


Pharmacy Practice

Professor
Focus: Endocrinology

Contact Information
(518) 694-7239
michael.kane@acphs.edu


Speaker Request
Michael P. Kane, PHARM.D., FCCP, BCPS, BCACP

EDUCATION

  • Pharm.D., Medical University of South Carolina 
  • Clinical Pharmacy Resident, Adult Internal Medicine, Medical University Hospital Medical University of South Carolina, Charleston, SC
  • Hospital Pharmacy Resident, Greenwich Hospital Association Greenwich, CT 
  • B.S., Albany College of Pharmacy and Health Sciences

COURSES TAUGHT AT ACPHS

  • Integrated Problem Solving Workshop 6 (Facilitator)
  • PTPM Endocrinology
  • APPE - Ambulatory Care Endocrinology/Internal Medicine rotation

RESEARCH INTERESTS

  • Assessing the safety and efficacy of new drugs in the management of diabetes mellitus and osteoporosis.

HONORS AND APPOINTMENTS

  • Recipient of the 2010 American College of Clinical Pharmacy, Clinical Practice Award; presented October 14, 2010, Austin, TX
  • Appointed to Board of Trustees of Northeast Kidney Foundation in 2015
  • 2018 - My biography has been accepted into Marquis Who's Who in the World (comprised of the top 3% of the professionals in the world)

CLINICAL AFFILIATIONS

  • Clinical Pharmacy Specialist – Albany Medical Center Division of Community Endocrinology (formerly The Endocrine Group), Albany, NY
  • Preceptor – Residency in Adult Internal Medicine/Endocrinology
  • Fellow of the American College of Clinical Pharmacy
  • Board Certified in Pharmacotherapy (since 1991)
  • Board Certified in Ambulatory Care Pharmacy (since 2011)

SCHOLARLY ACTIVITY

PUBLICATIONS

Stryker MD, Kane MP, Busch RS. Assessing the Real-World Use of Combination Insulin Glargine-Lixisenatide in Patients with Type 2 Diabetes Mellitus: A Retrospective Review from an Ambulatory Care Endocrinology Practice. Diabetes 2018;(Suppl 1):#2018-A-4059-Diabetes. (Abstract)

Stryker MD, Kane MP, Busch RS. A Real-World, Observational Study of Weekly Exenatide Added to Basal Insulin in Patients with Type 2 Diabetes Mellitus (NCT02895672). Endocrinol Diab Metab. 2017;00:e4. http://orcid.org/0000-0002-0648-6465.

Busch RS, Kane MP. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. Postgraduate Medicine. 2017;129 DOI: 10.1080/00325481.2017.1342509.

Kane MP. Endocrine Disorders. In: Bainbridge JL, Cardone K, Cross LB, et al. Updates in Therapeutics®: Ambulatory Care Pharmacy Preparatory Review and Recertification Course, 2017 ed. Lenexa, KS: American College of Clinical Pharmacy, 2017:1-262 - 1-322.

Stryker MD, Kane MP, Busch RS. Lack of Cross-Reactivity Allergy Following a Switch from Alirocumab to Evolocumab. Excerpts in Pharmacy Research Journal. 2016;2(1):1-2. Available at: http://digitalcommons.cedarville.edu/excerpts_in_pharmacy_research_journal/vol2/iss1/3

Stryker MD, Kane M, & Busch RS. A Pharmacist-Run Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Clinic: Short-Term Results and Practical Strategies. Pharmacotherapy, 2016;36(7), e111 (Abstract).

Stryker MD, Kane MP, Busch RS. An Evaluation Of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors In Patients With Diabetes Mellitus. J Clin Lipidol. 2016;10:720 (Abstract).

Saroka RM, Kane MP, Robinson L, Busch RS. No postoperative adrenal insufficiency in a patient with unilateral cortisol-secreting adenomas treated with mifepristone before surgery. Clinical Med Insights: Endocrinology and Diabetes. 2016;9:31-6. PMID: 27486349

Kane MP, Hamilton RA. Determination of the glycemic index of a diabetes truffle. Journal of Global Diabetes and Clinical Metabolism. 2016;1:22-4.

Brady SM, Kane MP, Busch RS. GLP-1 Agonist Use in a Patient with an Explainable Cause of Pancreatitis. AACE Clinical Case Reports. Spring, 2016. DOI 10.4158/EP15658.CR 

Jonklaas J, Kane MP. Thyroid disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach, 10th edition. New York, NY: McGraw-Hill Education, 2016:1183-1206.

Kane MP. Endocrine Disorders. In: Bainbridge JL, Cardone K, Cross LB, et al. Updates in Therapeutics®: Ambulatory Care Pharmacy Preparatory Review and Recertification Course, 2016 ed. Lenexa, KS: American College of Clinical Pharmacy, 2016:1-679 - 1-740.

 

SELECTED POSTER/PLATFORM PRESENTATIONS

*Stryker M, Kane MP, Busch RS. A Real-World, Observational Study of Weekly Exenatide Added to Basal Insulin in Patients with Type 2 Diabetes Mellitus (NCT02895672). Presented at the 27th AACE Annual Scientific and Clinical Congress Poster Presentations, May 18, 2018, Boston, MA.

*Stryker MD, *Bizier J, Kane MP. Follow-up real-world data in a proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibitor cohort: Results from a pharmacist-run clinic. Presented at the 2017 National Lipid Association Scientific Sessions, Philadelphia, PA, May 17, 2017.

*Bizier J, *Stryker MD, Kane MP. Extended-use proprotein convertase subtilisin/kexin type 9 Inhibitor (PCSK9i) data in patients with diabetes mellitus: A pharmacist-led initiative. Presented at the 2017 National Lipid Association Scientific Sessions, Philadelphia, PA, May 17, 2017.

Geriatrics Symposium: Osteoporosis Screening, Diagnosis and Treatment in Older Adults. Presented at the Albany College of Pharmacy and Health Sciences, March 16, 2017, Albany, NY.

ACCP 2017 Updates In Therapeutics: The Ambulatory Care Pharmacy Preparatory Review Course; Endocrine Disorders. Presented Endocrine Disorders section of the Ambulatory Care Pharmacy Preparatory Review Course which is offered in preparation of the pharmacy Specialty Certification Examination for Board Certification in Ambulatory Care. Presented February 17, 2017, Jacksonville, FL.

*Bizier J, Kane MP, Busch RS, Bakst G, ElDeiry SE, Hamilton RA. Efficacy and Safety of Switching Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor Therapy in Type 2 Diabetes Mellitus. 2016 ASHP Midyear Clinical Meeting, Las Vegas, NV, December 7, 2016.

Diabetes Update. Presented at the American Society of Consulting Pharmacists Mid-State New York Chapter Meeting and Education Day, June 16, 2016, Genesee Grand Hotel, Syracuse, NY.

Keynote Address: The Capital District Residency & Fellowship Graduation Luncheon. June 8, 2016, Hilton Garden Inn, Albany, NY.

*Stryker M, Kane MP, Busch RS, Hamilton RA. A pharmacist-run proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor clinic: short-term results and practical strategies. Presented at the ACCP Virtual Poster Symposium, May 18, 2016.

*Stryker M, Kane MP, Busch RS, Hamilton RA. An Evaluation Of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors In Patients With Diabetes Mellitus. Presented at the National Lipid Association Annual Meeting, May 18, 2016, New Orleans, LA.

Strategies for Diabetes Prevention. Presented at the Mid-Hudson Regional Hospital Pre-diabetes Epidemic Conference; Public Health Impact & Prevention of Type 2 Diabetes. Presented May 14, 2016, Sister M. Ann Elizabeth Conference Center, Poughkeepsie, NY.

ACCP 2016 Updates In Therapeutics: The Ambulatory Care Pharmacy Preparatory Review Course; Endocrine Disorders. Presented Endocrine Disorders section of the Ambulatory Care Pharmacy Preparatory Review Course which is offered in preparation of the pharmacy Specialty Certification Examination for Board Certification in Ambulatory Care. Presented April 9, 2016, Phoenix, AZ.

*Bizier J, Kane MP, Busch RS, Bakst G, ElDeiry SE, Hamilton RA. Efficacy and Safety of Switching Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor Therapy in Type 2 Diabetes Mellitus. 2016 ASHP Midyear Clinical Meeting, Las Vegas, NV, December 7, 2016.

The New Classes of Diabetes Medications: A Synopsis. Presented for Grand Rounds at the Baystate Medical Center, Springfield, MA, March 22, 2016.

Obesity Is a Chronic Disease: Let’s Treat it That Way. Presented at the 2016 APhA Annual Meeting, Baltimore, MD, March 7, 2016.

RESEARCH GRANTS

A Real World, Observational Study of Weekly Exenatide Added to Basal Insulin in Patients with Type 2 Diabetes Mellitus. Kane MP, Stryker M, Busch SA, Hamilton RA. Albany College of Pharmacy and Health Sciences and Albany Medical Center Division of Community Endocrinology (The Endocrine Group). Awarded $67,387; AstraZeneca Pharmaceuticals, LP; 6/16.

Determination of the Glycemic Index of Raw Amour Diabetes Truffle. Kane MP, Hamilton RA. Albany College of Pharmacy and Health Sciences. Awarded $1900; Raw Amour, 12/15.